^
5h
NCI-H292, a subtype of the NSCLC cell line, did not respond to SnMP treatment, possibly due to low basal levels of HO-1, suggesting a cellular-dependent antitumorigenic effect. Altogether, our results suggest HO activity inhibition may represent a potential target for selective chemotherapy in lung cancer subtypes.
Preclinical • Journal
|
TP53 (Tumor protein P53)
5h
Overexpression of PTEN partially reversed the cancer-promoting effect of miR-103a-3p. miR-103a-3p promotes the progression of NSCLC via Akt signaling by targeting PTEN, highlighting the role of miR-103a-3p/PTEN/Akt signaling and suggesting miR-103a-3p as a novel therapeutic target for NSCLC.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression
5h
Our study demonstrated the potential of multi-parametric MRI-based radiomics on preoperatively predicting the EGFR mutation. The proposed nomogram model can be considered as a new biomarker to guide the selection of individual treatment strategies for patients with thoracic spinal metastases from primary lung adenocarcinoma.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
5h
In LUAD, the enrichment in antigen presentation, MHC protein complex, and IFN-γ signaling, and low infiltration of neutrophils in primary or metastatic nodules may be indications for a favorable prognosis. Integrated with bioinformatics approaches, transcriptome data of immune-related genes from formalin-fixed, paraffin-embedded (FFPE) samples can effectively profile the landscape of the tumor immune microenvironment and help predict clinical outcomes.
Journal
|
IFNG (Interferon, gamma) • S100A8 (S100 Calcium Binding Protein A8)
5h
RNA sequencing dataset analyses detected that AAL may regulate the expression of JUN, TLR4, and MYD88 to suppress tumor proliferation. Through the pulmonary flora analysis, the bacterial structure of each phylum in the lectin treatment group was more reasonable, and the colonization ability of the normal microflora was improved, indicating that lectin treatment could significantly improve the bacterial diversity characteristics.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR4 (Toll Like Receptor 4) • JUN (Jun proto-oncogene)
5h
Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Alecensa (alectinib) • cyclosporin A microemulsion
9h
Clinically relevant tumors with complete or almost complete absence of MUC5AC staining included small cell carcinoma of the lung (0% of 17), clear cell renal cell carcinoma (0% of 507), papillary thyroid carcinoma (0% of 359), breast cancer (2% of 1097), prostate cancer (2% of 228), soft tissue tumors (0.1% of 968), and hematological neoplasias (0% of 111). The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.
Journal
|
MUC5AC (Mucin 5AC)
|
MUC5AC expression
9h
Moreover, MD simulations marked one construct as a promising therapeutic candidate. The multi-epitope vaccine constructs designed using immunogenic, and non-allergenic peptides of NSCLS tumor-associated proteins are likely to pose significant therapeutic efficacies in cancer immunotherapy due to their high binding affinities towards HLA molecules.
Journal • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • SLC7A11 (Solute Carrier Family 7 Member 11) • TLR4 (Toll Like Receptor 4)
9h
In this study, we introduce activin-A as a novel immunomodulatory factor in the lung tumor microenvironment, which bestows exhausted CD4 T cells with effector properties.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
9h
The most common grade {greater than or equal to}3 TEAE were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI-resistant cancers independent of resistance mechanisms, providing an approach to treating a broad range of drug-resistant cancers.
Clinical • Journal
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
EGFR mutation • ERBB3 expression • ERBB3 mutation
|
patritumab deruxtecan (U3-1402)
9h
We further developed a preclinical strategy to enhance the efficacy of HER3-DXd through osimertinib pre-treatment, which increased membrane expression of HER3 and led to enhanced internalization and efficacy of HER3-DXd. The combination of osimertinib and HER3-DXd may be an effective treatment approach and should be evaluated in future clinical trials in EGFR-mutant NSCLC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 overexpression • EGFR overexpression • ERBB3 expression
|
Tagrisso (osimertinib)
9h
Overall survival was significantly shorter in Exon20ins patients than in M-mut patients (29.3 vs. 43.4 months, p = 0.04). The clinical outcomes in Exon20ins patients were not satisfactory compared to M-mut patients.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
9h
In vivo, inhibition of MRTF-A effectively suppresses the growth of lung tumor syngrafts with enrichment of NK and T cells in tumor tissue. Our study defines a new signaling pathway that regulates the transcription and expression of PD-L1 upon TGF-β treatment, which may have a significant impact on research into the application of immunotherapy in treating lung cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • TGFB1 (Transforming Growth Factor Beta 1) • RELA (RELA Proto-Oncogene)
|
PD-L1 expression
9h
EGFR and KRAS genes showed obvious specific expressions in patients with different types of lung cancer and they were more common in patients with lung adenocarcinoma. Gene mutation and PDL1 expression are high in patients with lung adenocarcinoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
PD-L1 expression • KRAS mutation • EGFR mutation • PD-L1 overexpression • BRAF mutation • EGFR exon 18 mutation
9h
A potential mechanism underlying SPHK1‑induced cisplatin resistance and apoptosis inhibition may be activation of STAT3 via binding non‑POU domain containing octamer binding. In conclusion, the present study suggested that SPHK1 displayed significant antiapoptotic effects in cisplatin‑based treatment, thus may serve as a potential novel therapeutic target for the treatment for bladder cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
|
cisplatin • fingolimod
9h
Our findings suggested that afatinib is effective in patients with uncommon mutations. Mechanisms of afatinib resistance vary and need further investigation.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747P • EGFR A767_V769dup • EGFR H835L • EGFR L833V
|
Gilotrif (afatinib)
10h
Poziotinib showed promising antitumor activity in patients with HER2 exon 20 mutant NSCLC including patients who had previously received platinum-based chemotherapy.
Clinical • P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation • HER-2 exon 20 mutation
|
poziotinib (HM 78136B)
10h
In conclusion, our findings suggest that serum exosomal lncRNA SNHG15 might be a potential biomarker for early diagnosis and prognosis prediction of NSCLC.
Journal
|
SNHG5 (Small Nucleolar RNA Host Gene 5)
10h
In summary, this study confirmed the existence and oncogenic function of circ-WHSC1 in NSCLC. The research suggests that the circ-WHSC1/miR-7/TAB2 axis might be a potential target for NSCLC therapy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MIR7 (MicroRNA 7)
15h
P2, N=43, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Aug 2021 --> Dec 2021
Trial completion date
|
CD44
|
CD44 expression
13h
P1/2, N=263, Active, not recruiting, Sanofi | Trial completion date: Sep 2021 --> Mar 2022
Trial completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 positive • CEACAM5 expression
|
tusamitamab ravtansine (SAR408701)
15h
P=N/A, N=121, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Apr 2021 --> Mar 2022
Trial completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR expression • EGFR R776H
19h
Synopsis Assess the mechanism of action and preclinical profile of HER3-DXd Examine the clinical development of HER3-DXd in non-small cell lung cancer (NSCLC) Discuss the future development of HER3-Dxd
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
patritumab deruxtecan (U3-1402)
21h
New P2 trial
|
KRAS (KRAS proto-oncogene GTPase)
|
Lumakras (sotorasib) • SAR442720
19h
Enrollment open
|
HRD (Homologous Recombination Deficiency)
|
RP12146
1d
In this context, we identified Mcl-1 as a resistance factor that interfered with apoptosis induction by ABT-263, ionizing radiation, and combinatorial treatment. Collectively, our findings provide novel insights into the molecular determinants of hypoxia-mediated resistance to apoptosis and radiotherapy and a rationale for future therapies of hypoxic and hypoxia-selected tumor cell fractions.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
1d
Phosphorylation of key proteins, including p38 MAPK, ERK, PI3K, STAT3, and p53, modified by NO in various signaling pathways affects different cancer-related processes including cell apoptosis, proliferation, angiogenesis, metastasis, and several cancer therapies. Our review links the NO signaling pathway to protein phosphorylation in cancer development and provides new insight into potential targets and cancer therapy.
Review • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
1d
Of the 782 patients who received first-line (1L) therapy with first-/second-generation EGFR TKIs in the cohort A, erlotinib was the most common (58%), and osimertinib was the most widely prescribed second-line (2L) therapy (52%). The majority of patients treated with first-/second-generation EGFR TKIs went on to receive osimertinib in the 2L setting, but overall, only a third of patients had received molecular testing at progression. Improved testing frequency is vital to inform treatment decisions.
Clinical • Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
erlotinib • Tagrisso (osimertinib)
1d
Adjuvant chemotherapy increased various lipid levels in resected NSCLC patients. A higher HDL-C level before chemotherapy and a reduced HDL-C level after adjuvant chemotherapy were independent predictors of longer DFS in patients with curable NSCLC.
Observational data • Retrospective data • Journal
|
APOB (Apolipoprotein B)
1d
Based on the results, we concluded that UCA1 promoted LUAD progression and cisplatin resistance and hence could be a potential diagnostic marker and therapeutic target in patients with LUAD.
Journal
|
ENO1 (Enolase 1) • PCNA (Proliferating cell nuclear antigen)
|
cisplatin
1d
For SMPLA with ≥ 3 lesions, one-stage resection may be safe and feasible, and surgical procedure was mainly sublobar resection as far as possible, which can yield satisfactory prognosis. EGFR mutation testing should be used routinely in the diagnosis and treatment of patients with SMPLA, especially in the presence of mGGO and invasive adenocarcinoma.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
1d
This prospective study demonstrates the utility of the 14-gene assay independent of EGFR mutation. Basing adjuvant intervention in early-stage NSCLC on EGFR status alone may undertreat up to 51% of EGFR(-) patients likely to benefit from adjuvant intervention, and overtreat as many as 67% of EGFR(+) patients more likely to be free of residual disease.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
1d
While the contribution of OIS to disease progression is undetermined, recent evidence suggests that senescent cells are permissive for malignant transformation. Accordingly, the pharmacological targeting of oncogene-induced senescent cells could potentially provide a novel means for the treatment of premalignant disease.
Journal
|
BRAF (B-raf proto-oncogene)
1d
We investigated the impact of alternative dosing regimens on progression-free survival (PFS), overall survival (OS), and the probability of developing a grade ≥2 rash or grade ≥2 amylase increase. Median PFS and OS increased by 1.6 and 7.8 months, respectively between the currently approved dosing strategy and precision dosing to the median trough concentration of the 240mg dosing strategy, with only a minor increase in the probability of developing toxicity.
Clinical • PK/PD data • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alunbrig (brigatinib)
1d
Pembrolizumab plus platinum-based chemotherapy prevailed in rank in OS, PFS, and ORR benefit. The TRAEs of pembrolizumab plus platinum-based chemotherapy were more than ICI monotherapy and chemotherapy.
Retrospective data • Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab)
1d
APC gene promoter methylation in serum or sputum/BLAF is a potential biomarker for lung cancer diagnosis with high specificity. However, due to its low sensitivity, it may not be suitable for lung cancer screening in the general population.
Retrospective data • Journal
|
APC (APC Regulator Of WNT Signaling Pathway)
1d
A multivariate model comprising age, carcinoembryonic antigen levels, and mutation status allowed the identification of a truly high-risk group of BM in NSCLC patients.
Clinical • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
1d
FZKA could directly bind to CCNA2 and inhibit tumor growth by regulating CCNA2 downstream genes and TME of NSCLC closely related to CCNA2.
Journal
|
CCNA2 (Cyclin A2)
1d
Regarding pharmaceutical radiosensitization, these findings provided a way to improve high-LET clinical radiotherapy for NSCLC patients.
Preclinical • Journal
|
CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis) • CASP9 (Caspase 9)
1d
Finally, clinical investigations further demonstrated that UBQLN1 level was positively correlated with patient's survival of lung adenocarcinoma, but not squamous cell carcinoma of lung. Taken together, our results revealed a novel mechanism involving ROS homeostasis and mitochondrial biogenesis in non-small cell lung CSCs, which may provide novel potential targets and methods for NSCLC patients.
Journal
|
ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
1d
Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using phase I/II PK data in crizotinib-failed patients (N = 138). These pharmacometric results were used to expedite and facilitate regulatory approvals of 600 mg b.i.d. for first-line ALK-positive NSCLC in the United States and European Union in 2017 and in China in 2018.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Alecensa (alectinib)
1d
Serum level of plasma HSP90α could be a reliable biomarker in diagnosing lung cancer and its subtypes and might be a valid biomarker for predicting lung cancer relapse in patients treated with chemoradiotherapy and surgery.
Journal
|
HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
2d
P1/2, N=13, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Sep 2021
Trial completion • Trial completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation
|
ibrutinib
2d
P2, N=18, Recruiting, Spanish Lung Cancer Group | Trial completion date: May 2022 --> Oct 2023
Trial completion date
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
2d
P3, N=453, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Apr 2026
Enrollment closed • Trial completion date
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • carboplatin • Tecentriq (atezolizumab) • gemcitabine • Abraxane (albumin-bound paclitaxel) • pemetrexed
2d
P1, N=234, Recruiting, Xencor, Inc. | Trial completion date: Mar 2025 --> Dec 2024
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
2d
P2, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Apr 2022 --> Jul 2022
Trial completion date
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
2d
P2, N=31, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2023 --> Mar 2029
Trial completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK rearrangement • MET mutation
|
spartalizumab (PDR001) • Tabrecta (capmatinib)
2d
P1b/2, N=375, Recruiting, Pfizer | Trial primary completion date: Nov 2024 --> Dec 2025
Clinical • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • BRAF V600E • BRAF V600
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Inlyta (axitinib) • sasanlimab (PF-06801591) • SGN-TGT
2d
P1, N=48, Recruiting, AO GENERIUM | Trial completion date: Nov 2024 --> Jun 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
Clinical • Trial completion date • Trial primary completion date
|
PD-1 (Programmed cell death 1)
|
GNR-051
2d
P1, N=18, Active, not recruiting, Sichuan University | Not yet recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
2d
Mechanistically, we discovered that NSCLC cell-derived exosomal lncRNA-SOX2OT modulated osteoclast differentiation and stimulated BoM by targeting the miRNA-194-5p/RAC1 signalling axis and TGF-β/pTHrP/RANKL signalling pathway in osteoclasts. In conclusion, exosomal lncRNA-SOX2OT plays a crucial role in promoting BoM and may serve as a promising prognostic biomarker and treatment target in metastatic NSCLC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
2d
At biochemical level, we further identified that cADPR, the mainly hydrolytic product of CD38, was responsible for inducing the opening of TRPM2 iron channel leading to the influx of intracellular Ca and then led to increasing levels of NRF2 while decreasing expression of KEAP1 in lung cancer cells. These findings suggested that malignant lung cancer cells were capable of using cADPR catalyzed by CD38 to facilitate tumor progression, and blocking the enzymatic activity of CD38 could be represented as an important strategy for preventing tumor progression.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule)
|
CD38 expression • KEAP1 expression
2d
We investigated a role of p53 elevation by MDM2 inhibitors, nutlin-3a and RG7112, in cytotoxicity of replication-competent adenoviruses (Ad) lacking the p53-binding E1B55kDa gene (Ad-delE1B). We also demonstrated anti-tumor effects by the combination of Ad-delE1B and the MDM2 inhibitors in an orthotopic animal model. These data collectively indicated that upregulation of wild-type p53 expression contributed to cytotoxicity by E1B55kDa-defective replicative Ad through NFI induction and suggested that replication-competent Ad together with augmented p53 levels was a therapeutic strategy for p53 wild-type mesothelioma.
Journal
|
CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • CHEK2 (Checkpoint kinase 2)
|
TP53 mutation • TP53 expression
|
Nutlin-3 • RG7112
2d
The expression of SOX17 is necessary and sufficient to drive a second wave of epigenetic changes in LKB1-deficient cells that enhances metastatic ability. Overall, our study demonstrates how the downstream effects of an individual driver mutation can change throughout cancer development, with implications for stage-specific therapeutic resistance mechanisms and the gene regulatory underpinnings of metastatic evolution.
Journal
|
STK11 (Serine/threonine kinase 11) • SOX17 (SRY-Box Transcription Factor 17)
2d
Through the addition of an adequate oxidant and catalase, the catechol-conjugated alginate (C-ALG) hydrogel showed rapid gelation for less than 5 min, similar mechanical properties to lung tissue, slight swelling degree, good cell compatibility, and enough tissue adhesion for localization around the lung tissue. In addition, the C-ALG hydrogel increased the bursting pressure of lung tissue up to 266 ± 15-385 ± 13 mm-HO that could prevent hydrogel rupture and migration during localizing surgery, suggesting the injectable hydrogel with effectiveness and safety for clinical applications.
Clinical • Journal
|
CAT (Catalase)
2d
It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Furthermore, it illustrates the multifactorial nature of cisplatin resistance by examining the diversity of dysregulated pathways present in cisplatin-resistant NSCLC cells based on KEGG pathway analysis.
Review • Journal
|
TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
cisplatin
2d
Mechanistically, tumour α regulates CD8 T cell recruitment, induces CD103 expression on activated CD8 T cells and promotes their differentiation to granzyme B-producing CD103CD69 resident memory T cells via autocrine TGF-β signalling. Thus, our work provides the underlying principle of targeting cancer cell α for more efficient PD-1 checkpoint blockade therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • CD69 (CD69 Molecule) • ITGAE (Integrin Subunit Alpha E)
|
CD8 expression
2d
These findings suggested that circ_PIP5K1A upregulated the ROCK1 expression to promote DDP resistance and cancer progression in NSCLC by sponging miR-493-5p.
Preclinical • Journal
|
PIP5K1A (Phosphatidylinositol-4-Phosphate 5-Kinase Type 1 Alpha)
|
cisplatin
2d
Importantly, treatment of LY294002 (an inhibitor of the PI3K/Akt pathway) attenuated miR-17-5p-mediated osteoclastogenesis effects. Taken together, our findings demonstrated that miR-17-5p promotes osteoclastogenesis through the PI3K/Akt pathway via targeting PTEN in lung cancer.
Journal
|
PTEN (Phosphatase and tensin homolog) • CSF1 (Colony stimulating factor 1) • MIR17 (MicroRNA 17)
|
quercetin (LY294002)
2d
At ALTA-1L final analysis, with longer follow-up brigatinib continued to demonstrate superior efficacy and tolerability versus crizotinib in patients with or without poor prognostic biomarkers. The suggested survival benefit with brigatinib in patients with brain metastases warrants future study.
Clinical • P3 data • Journal
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
|
TP53 mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation
|
Xalkori (crizotinib) • Alunbrig (brigatinib)
2d
Moreover, western blot data showed that NC suppressed the expression of Lats1, Mob1, and YAP, and enhanced the expression of p-Lats1, p-Mob1, p-YAP1 (ser127). Overall, our research reveals that NC exerts anticancer activity by activating and modulating the Hippo signaling pathway.
Journal
|
YAP1 (Yes associated protein 1)
2d
Furthermore, a bright correlation was obtained for CYFRA 21-1 detection in the clinical serum samples. By merits of its ease of operation, environmental friendliness and low cost, this method had considerable potential application in bioanalytical for the ultrasensitive quantitation of biological molecules.
Journal
|
KRT19 (Keratin 19)
2d
For instance, pathways resulting in uncontrolled growth and proliferation of tumour cells due to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements may be targeted by tyrosine kinase inhibitors (TKIs). In this article, we review the current state of medical oncology, imaging characteristics of mutations, pitfalls in response assessments and the imaging of complications.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
2d
With the current report, we present the case of a 75-year-old woman diagnosed with stage IV lung adenocarcinoma, who developed acute abdominal pain without preceding symptomatology while on pembrolizumab-pemetrexed maintenance treatment. Subsequent endoscopic as well as histopathological findings from biopsies obtained via colonoscopy associated the clinical and imaging findings with grade 4 immune-mediated colitis. Interestingly, high-grade colitis is more frequent with anti-CTLA-4 agents in comparison to anti-PD-1 agents; moreover, most cases of anti-PD-1-mediated colitis present with preceding symptomatology (like diarrhea or vomiting), while cases or colonic perforation are extremely rare if ever described.
Clinical • Review • Journal
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • pemetrexed
2d
TNFα treatment upregulated the five genes expression, while the BET-bromodomain inhibitor JQ1 restored the effect of TNFα. Overexpression of the five genes significantly inhibited the proliferation of A549 and H1299 cells. GDF10, HPGDS, ABCA8, SLIT3 and ADAMTS8 were identified as enhancer-regulated prognostic inflammation-related biomarkers, and the expression of these genes inhibited proliferation of LUAD cells.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
TNFA overexpression
|
JQ-1
2d
In 100 patients with LUAD, the high-risk group with an immunosuppressive state had a higher expression of PD-L1 and lower counts of CD8+ T cells and dendritic cells. These findings demonstrated that combined multi-omics data could determine molecular subtypes with significant differences of prognosis and TIME in LUAD and suggested potent utility of the signatures to guide immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin)
|
PD-L1 overexpression
2d
Our results indicated that 7 DEcircRNAs could have diagnostic value for LUAD. Additionally, the circRNAs-mediated ceRNA network might provide a novel perspective into unraveling the pathogenesis and progression of LUAD.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
2d
Western blot analysis further demonstrated that DLGAP5 knockdown downregulated the expression of CDK1, Cyclin B1 and Bcl-2, but upregulated Bax expression. Collectively, these data demonstrate that DLGAP5 might be a promising prognostic therapeutic target for OC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
BCL2 expression • BAX expression
2d
Our data provide an insight into the molecular mechanisms of radiation resistance and suggest that EG00229 may contribute to reversing the radiation resistance of NSCLC cells by inhibiting the binding of NRP1 and VEGF-165. Our findings could provide a novel theoretical and experimental foundation for improving the efficacy of lung cancer radiotherapy.
Journal
|
NRP1 (Neuropilin 1)
2d
In spite of the increasement of β-catenin, activation of Wnt pathway and EMT progression, knockdown of Axin leaded to de-function of OP-B on cell metastasis. Taken together, OP-B reduced NSCLC migration and invasion by strengthening the Axin/β-catenin interaction and reducing β-catenin protein translocation.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • AXIN1 (Axin 1)
2d
Down-regulation of lncRNA MALAT1 expression may promote apoptosis of CSCC cells and inhibit cell migration, invasion and proliferation by regulating the Wnt signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • VIM (Vimentin)
|
BCL2 expression • CDH1 expression • VIM expression
2d
Moreover, it assisted in further understanding of the molecular pathogenesis of co-expression of modular genes that regulate LUAD and LUSC. It provided a precious resource and theoretical basis for further experiments.
Journal
|
MIR335 (MicroRNA 335) • RELA (RELA Proto-Oncogene) • COL5A1 (Collagen Type V Alpha 1 Chain)
2d
The respiratory function training under the mode of mutual-assist of patients can effectively reduce the incidence of postoperative pulmonary infection, improve the postoperative pulmonary function index, and improve the immune function, which is worthy of clinical promotion.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
2d
Patients benefit overall survival from enhanced CIK therapy in our clinical study. Our present preclinical and clinical studies for the first time elucidated that these enhanced CIK cells would be used as an effective adjuvant therapy in the treatment of RCC.
Preclinical • Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • GZMB (Granzyme B)
2d
Similar to reports from other populations, our results suggest that programmed death ligand-1 expression in non-small cell lung cancer is highly prevalent in the Lebanese population, especially in patients with advanced stage at diagnosis or squamous cell carcinoma histology. Because of the small sample size, while more that 60% of the patients are Lebanese, the results of this article cannot be extrapolated to the Middle Eastern and the Levantine population.
Clinical • Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
2d
Our results expand the germline mutation spectrum in malignant GGO nodules. Importantly, these findings will potentially help screen the high-risk population, guide their health management, and contribute to their clinical treatment and determination of prognosis.
Clinical • Journal
|
RAD50 (RAD50 Double Strand Break Repair Protein) • NOTCH3 (Notch Receptor 3) • LMO2 • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A)
|
RAD50 mutation
2d
No significant difference in PFS was observed between afatinib and 1G TKI in combination with chemotherapy (P = 0.709). Like afatinib, 1G TKI in combination with chemotherapy might be an effective treatment option for patients harboring EGFR exon 18 mutations.
Clinical • Clinical data • Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR G719X • EGFR exon 18 mutation
|
Gilotrif (afatinib)
2d
A CMap analysis identified 13 small molecule drugs as potential agents based on the risk model for LUAD treatment. Thus, we identified a prognostic risk model including CBFA2T3, CR2, SEL1L3, TM6SF1, TSPAN32, ITGA6, MAPK11, RASA3, and TLR6 as novel biomarkers and validated their prognostic and predicted values for LUAD.
Journal • Gene Signature
|
MAPK1 (Mitogen-activated protein kinase 1) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • SEL1L3 (SEL1L family member 3) • ITGA6 (Integrin, alpha 6)
2d
Both patients demonstrated improved survival after they switched to second-line crizotinib (PFS: 11 months) and ensartinib (PFS: 18 months), respectively, up till the last follow-up assessment. This study and literature review results showed mixed responses to alectinib in NSCLC patients who harboured rare ALK fusions. Comprehensive molecular profiling of tumour is thus strongly warranted for precise treatment strategies.
Clinical • Review • Journal
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • STRN (Striatin)
|
MET amplification • ALK positive • ALK rearrangement • ALK fusion • STRN-ALK fusion
|
Xalkori (crizotinib) • Alecensa (alectinib) • ensartinib (X-396)
2d
Western blot analysis revealed significant downregulation for various RAS downstream proteins postoncogene knockdown. Comparison of the efficiency of GADS vis-à-vis positive siRNA control and CRISPR-Cas9-based knockout of KRAS Exon 2 in the NCI-H23 NSCLC cell line suggests GADS as a potential technology for clinical translation of gene therapy.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12 • KRAS exon 2 mutation
|
Erbitux (cetuximab) • gefitinib
2d
We found that immune checkpoint inhibitors significantly prolonged OS over docetaxel overall (HR 0.71, 95% CI 0.64-0.79) and in the EGFR wild type (HR = 0.67, 95% CI = 0.60-0.75), but not in the EGFR mutant subgroup (HR = 1.11, 95% CI = 0.80-1.52)...Harbord's weighted linear regression test (P = 0.956) and Peters regression test (P = 0.489) indicated no significant publication bias. The limited benefit of single-agent PD-1/PD-L1 inhibitors in the second-line or later setting for EGFR-mutated NSCLC may be partly due to the lower expression of PD-L1.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
PD-L1 expression • EGFR mutation
|
docetaxel
2d
Our findings indicated that there is a correlation between diffusion parameters as imaging biomarkers of the solid component of brain metastases of primary tumours and the tumour histology.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative
2d
Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival versus chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score ≥50%. The trial is registered with Clinicaltrials.gov: NCT02142738.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab)
2d
The ATRA has decreased the inflammatory condition with downregulation of COX-2 gene expression and thereby prevented carcinogenesis during early stage of B(a)P induced cancer development.
Preclinical • Journal
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
2d
Our research suggests that DICER promotes autophagy and DDP resistance in NSCLC through downregulating let-7i-5p, and inhibits the activation of PI3K/AKT/mTOR pathway.
Journal
|
DICER1 (Dicer 1 Ribonuclease III)
|
cisplatin • sirolimus
2d
In a proof-of-concept experiment for detecting circulating 15n-del EGFR mutation, a detection limit of 0.8 fM and a linear detection range of 1 fM to 100 pM was achieved, and an accuracy of 100% was reached in clinical validation by analyzing 20 samples from clinical lung cancer patients. Empowered by the intrinsic sensitivity and selectivity, the proposed PASTA approach will lead to the development of a universal platform for reliable molecular subtyping.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
2d
Thus, our findings reveal important targets and highlight the significance of the crosstalk between STAT3 and mTOR signaling in cisplatin resistance. The synergic inhibition of STAT3 and mTOR potentially unveil a potential mechanism of synthetic lethality to be explored for human lung cancer treatment.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
cisplatin
2d
Osimertinib-chemotherapy combination had a manageable safety and tolerability profile in EGFRm advanced/metastatic NSCLC, supporting further assessment in the FLAURA2 randomized phase.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
2d
Our results support the rationale for using TKIs during pregnancy, both in terms of maternal NSCLC disease control and the relatively mild effects on the fetus. Our data will serve to better inform patients about the risks associated with TKIs used during pregnancy, contributing to shared decision making.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Herceptin (trastuzumab) • Tagrisso (osimertinib)
3d
P3, N=52, Terminated, Novartis Pharmaceuticals | Completed --> Terminated; Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.
Clinical • Trial termination
|
EGFR (Epidermal growth factor receptor)
|
HER-2 overexpression
|
lapatinib • capecitabine
3d
VISION is the first trial of a MET inhibitor to provide data on PROs and utilities in NSCLC harboring METex14 skipping mutation. EORTC and EQ-5D (minimally important difference: 0.08) utilities show an increase in HRQoL from baseline during tepotinib treatment until progression. Utility with tepotinib did not vary by prior treatment status or histology.
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation
|
Tepmetko (tepotinib)
3d
Patients with ≥1 claim for an EGFR TKI (1st generation [1G]: gefitinib, erlotinib; 2nd generation [2G]: afatinib, dacomitinib; 3rd generation: osimertinib) from January 1, 2015 – April 30, 2020 were identified in IQVIA’s prescription (LRx) and medical claims (Dx) databases; first date of EGFR TKI was the index date. In real-world practice, 1L treatment duration is longer with osimertinib compared with other EGFR TKIs. Future studies with longer follow-up are recommended to understand treatment patterns after progression on EGFR TKIs, mainly osimertinib, given its recent approval.
Clinical • HEOR • Real-world evidence • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
erlotinib • Gilotrif (afatinib) • Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)
3d
The adoption of NGS differed by cancer type and NGS testing rates have increased over time in aNSCLC and mBC. While some pts may have received testing outside of the Flatiron network, OO had a higher NGS uptake than NAT, and had a shorter time to testing in mBC that was possibly related to a network wide strategy recommending testing at Dx of advanced disease. Future studies on tx pattern after NGS testing are warranted to improve the actionability of NGS to foster personalized tx.
Next-generation sequencing • BRCA Biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset)
3d
Findings from this study demonstrated an increase in aNSCLC biomarker testing at OneOnc over time, while 44% pts in 2020 did not receive testing on all 6 biomarkers. Some pts had tx prior to the test result, but this trend appeared to decline. Further studies are warranted to better understand the reasons for pts receiving tx that were not specific to their actionable mutations.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF mutation
3d
NGS testing utilization increased during the study period and by 2019, 59% of patients received NGS-based testing. Opportunities persist for practices to improve testing and achieve guideline recommendations. PD-L1 biomarker testing was performed amongst the highest proportion of patients in this study and nearly 50% of all patients received immunotherapy, including checkpoint inhibitors.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • EGFR mutation • BRAF mutation • RET fusion • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 fusion • MET mutation • ROS1 rearrangement • NTRK expression • NTRK fusion
3d
Although improving, a substantial number of registrational clinical trials in thoracic oncology still do not report race per FDA guidance. In addition, Black individuals are disproportionately under-represented in registration trials. Greater efforts are needed for the inclusion of Black patients and other minorities in clinical trials.
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
3d
In this real-world retrospective review of patients with advanced NSCLC, there was an increased uptake of systemic therapy for both age groups with the introduction of novel therapeutics. Although there was a smaller proportion of older adults who received systemic therapy, those who received treatment had comparable OS to their young counterpart. The benefit of systemic therapy in both age groups was seen across the different types of treatments.
Clinical
|
EGFR (Epidermal growth factor receptor)
3d
The proportion of aNSCLC patients tested for EGFR mutations has increased over time (2015-2020). Median time to available EGFR test result has decreased for both NGS and PCR tests. NGS testing has become increasingly more common as has use of plasma samples.
Clinical • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
3d
Incorporation of concurrent T+P NGS testing in treatment naïve metastatic non-Sq NSCLC significantly increased the proportion of patients undergoing guideline concordant molecular testing, including prior to initiation of first-line therapy at our institution. Concurrent T+P NGS should be adopted into institutional pathways and routine clinical practice.
Clinical • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
3d
Online forums, particularly those that narrowly focus on specific diseases or treatments, provide patients and caregivers with anecdotal evidence that helps them with practical matters, such as how to manage side effects, as well as more existential issues, such as how long they can expect to live. These results suggest that clinicians should be open to and curious about the information that patients and caregivers learn from online forums in order to better understand the perspectives that patients and caregivers bring to discussions and decisions about their cancer.
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
3d
This study aims to identify gaps in health disparities in gender, race/ethnicity, and insurance type for genomic testing that should be standard practice. Future investigation and attention to this issue appears necessary to begin moving from documenting disparities, to understanding them, and ultimately to reducing them.
Clinical
|
EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
3d
P1b, N=169, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
3d
P1/2, N=68, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=98 --> 68
Enrollment closed • Enrollment change
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
|
BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • nintedanib
3d
The findings suggest a novel role for MCs in the development of lung fibrosis via TGF-β production-induced myofibroblast differentiation.
TGFB1 (Transforming Growth Factor Beta 1) • ACTA2 (Actin Alpha 2 Smooth Muscle) • IL33 (Interleukin 33)
3d
In this large study of patients who received an ICI, we found melanoma, GU cancer, pre-existing autoimmune disease, and glucocorticoid use within 1 year of ICI may be novel predictors of rheumatic irAEs. The possible biologic basis of these associations should be the subject of future research.
Adverse events • Checkpoint inhibition
|
PD-1 (Programmed cell death 1)
3d
P1/2, N=88, Recruiting, Sanofi | Trial completion date: May 2024 --> Jul 2025 | Trial primary completion date: May 2024 --> Jul 2025
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NF1 (Neurofibromin 1)
|
KRAS mutation • BRAF mutation • NF1 mutation • BRAF amplification
|
Keytruda (pembrolizumab) • SAR442720
3d
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
3d
Median TTDD for cough and chest pain was NE in both 1L and 2L+ patients, and for dyspnea was 19.4 mo (95% CI: 12.4, NE) and 22.1 mo (95% CI: 9.9, NE), respectively. QLQ-LC13 symptoms improved at all cycles in patients achieving clinical complete response or partial response, while symptom worsening was seen in those with no clinical response.Capmatinib was associated with clinically meaningful improvements in cough, delayed time to lung symptom deterioration, and preserved QoL, supporting its use as a treatment option in patients with METex14-mutated NSCLC.
Clinical • P2 data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET mutation
|
Tabrecta (capmatinib)
3d
The updated survival outcomes from the PACIFIC trial will provide insight into long-term survival benefit with durvalumab following cCRT. Encore of ASCO 2021 presentation. Funded by AstraZeneca.
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab)
3d
Tepotinib showed robust and durable clinical activity across therapy lines, as expected when targeting an oncogenic driver. Peripheral edema was the most common AE; most AEs were mild-moderate with few discontinuations.
Clinical
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation
|
Tepmetko (tepotinib)
3d
Taken together our data clearly point to RIPK3 as a tumor suppressor in LUAD. This effect may be driven by the inhibition of necroptotic cell death, which in turn alters immune cell recruitment. Leveraging the crosstalk between inflammatory cell death and immune micro-environment may be a possible immunogenic therapeutic target.
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • RIPK3 (Receptor Interacting Serine/Threonine Kinase 3)
|
KRAS G12D • TP53 deletion • KRAS G12 • KRAS deletion
3d
Patients (pts) with non-squamous NSCLC in the chemo-alone arm could receive pemetrexed maintenance. With 2 yr minimum FU, 1L NIVO+IPI+chemo demonstrated durable survival and benefit versus chemo in pts with advanced NSCLC; no new safety signals were identified.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • pemetrexed
3d
These results demonstrate the effectiveness of consolidation durvalumab after CRT in a real-world cohort of pts with unresectable Stage III NSCLC; pneumonitis events were mostly moderate in severity. Additional data from an externally sponsored study with similar enrolment criteria in Spain will be included in the final presentation.
Clinical • Real-world evidence
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab)
3d
Median PFS (mPFS) for all analyzable treatments (all lines) was 6.6 months for EGFR-TKIs vs. 4.9 months for chemotherapy in group 1 (HR 0.54, 95%CI 0.35 to 0.81, P = .003, n=134) and 6.7 months vs. 3.5 months in group 3, respectively (HR 0.68, 95%CI 0.48 to 0.95, P = .024, n=169).Afatinib (A) was the most frequently administered TKI in both groups (46% and 51% in group 1 and 3, respectively)...MPFS in group 1 was 3.8 months with erlotinib (E, 29%), 9.1 months with gefitinib (G, 16%) and 5.0 months with osimertinib (O, 10%, overall log rank 0.014]... This real-world dataset confirms that patients with uncommon (group 1) and very rare EGFR mutations (group 3) benefit from EGFR-TKIs compared to chemotherapy. The comparison between the TKIs needs to be interpreted with caution due to small sample size. Altogether, the group of very rare EGFR mutations needs to be functionally characterized.
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
|
erlotinib • Gilotrif (afatinib) • Tagrisso (osimertinib) • gefitinib
3d
30 pts out of 41 eligible (best response CR/PR/SD) received consolidation therapy with durvalumab. CRISP presents comprehensive current real-life data of patients with NSCLC in stage II or III covering all treatment settings in Germany. With longer follow-up outcome in routine care will be analyzed.
Clinical • HEOR • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Imfinzi (durvalumab)
3d
BRG showed sustained long-term activity and manageable safety in CRZ-refractory ALK+ NSCLC. The 180-mg qd dose (7-day lead-in at 90 mg) led to numerically higher median PFS and OS. Final results are similar to those reported for other ALK TKIs in this setting.
Clinical • P1/2 data • P2 data
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Alunbrig (brigatinib)
3d
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
3d
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
4d
P2, N=30, Recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Conmana (icotinib) • befotertinib (D-0316)
4d
At the time of her first presentation, she had been receiving injections of bevacizumab every 4 weeks for 3 months...If the BAP1 tumor predisposition syndrome is present, the patient must be given genetic advice and receive appropriate preventive and follow-up care from a specialist. Since a choroidal melanoma with BAP1 mutation is particularly aggressive, further imaging follow-up can be discussed in the first few years of diagnosis.
BAP1 (BRCA1 Associated Protein 1)
|
BAP1 mutation
|
Avastin (bevacizumab)
4d
We initiated palliative immunotherapy with the PD-1 antibody pembrolizumab...We initiated palliative immunotherapy with the PD-1 antibody pembrolizumab...We initiated palliative immunotherapy with the PD-1 antibody pembrolizumab...We initiated palliative immunotherapy with the PD-1 antibody pembrolizumab...We initiated palliative immunotherapy with the PD-1 antibody pembrolizumab...So far there is no evidence regarding the adequate treatment of endobronchial melanoma metatases. Clinical studies will therefore be necessary in the future to improve the outcome and quality of life of these patients.
PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
Keytruda (pembrolizumab)
4d
In humanized lung cancer xenografts and a syngeneic Egfr-driven lung cancer model these effects translate into reduction of exhausted CD8 T cells and robust tumor shrinkage. Overall, the mechanistic understanding of MAPK/IRF1-mediated intratumoral reprogramming may ultimately prolong the efficacy of targeted drugs in genetically defined cancer patients.
Journal
|
EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • IRF1 (Interferon Regulatory Factor 1)
|
IRF1 expression
4d
A robust population PK model was built and qualified for entrectinib and M5, describing linear PK for both entities. This model was used to support the ROZLYTREK new drug application.
Clinical • NDA • PK/PD data • Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 positive • ROS1 fusion • NTRK fusion
|
Rozlytrek (entrectinib)
4d
PFS of the prior EGFR-TKI treatment, performance status score and bone metastasis were independent prognosticators of the osimertinib treatment. These findings may facilitate clinicians in the decision-making of osimertinib.
Clinical • Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
4d
An in-depth study of the structure and biological activities of NSD1 sets the groundwork for improving tumor therapy and creating NSD1 inhibitors. This article emphasizes the role of NSD1 in tumorigenesis and the development of NSD1 targeted small-molecule inhibitors.
Journal
|
NSD1 (Nuclear Receptor Binding SET Domain Protein 1)
4d
Based on its promising clinical efficacy and tolerability profile, monotherapy with low-dose afatinib should become one of the standard therapies for EGFR mutation-positive NSCLC.
Clinical • P2 data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Gilotrif (afatinib)
4d
Sequential DNA and RNA based molecular profiling increased the efficacy of detecting fusion driven NSCLCs. Continued optimisation of tissue procurement, handling and the diagnostic pathways for gene fusion analysis is necessary to reduce analysis failure rates and improve detection rate for treatment with the next generation of small molecule inhibitors.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR (Fibroblast Growth Factor Receptor)
|
ALK fusion
5d
Compounds 11 and 12 decreased phosphorylation of EGFR and downstream signaling protein, which also have more hydrophobic interactions than EGCG by docking study. The most active compounds 11 and 12, both having perbutyrylated glucose residue, we found that perbutyrylation of the glucose residue leads to increased cytotoxic activity and suggested that their potential as anticancer agents for further development.
Journal
|
EGFR (Epidermal growth factor receptor)
5d
These results revealed that WSPM from rare earth mines decreased the viability of A549 cells, and induced cell cycle G2/M phase arrest, and even apoptosis, which may be independent of the NF-κB/MYD88 pathway, and be perceived by the TLR4 receptor. The dysfunction of the cell cycle is correlated to the down-expression of ribosomal proteins (RPs). However, it is not the direct reason for the A549 cell arrest in the G2/M phase. La, Ce, and F are probably the main toxic substances in WSPM, and may be regulate the A549 cell cycle by affecting the expression of genes, such as MDM2, RB1, ATM, TP53, EF, CDK2 and CDK4. These results indicate the importance for further research into the relationship between APM and lung cancer.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CHEK2 (Checkpoint kinase 2) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • TLR4 (Toll Like Receptor 4) • CCNB1 (Cyclin B1) • CDC25A (Cell Division Cycle 25A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
CCND1 expression • TP53 expression • ATM expression • CDK2 expression
5d
Compared with the CBM, the MCM can improve the efficiency of DNA/RNA extraction and PCR amplification by removing impurities and enriching tumor cells. And we speculate that the successful detection rate of fresh cytological specimens was higher than that of paraffin-embedded specimens. EGFR, ALK, and ROS1 mutations were the main driver mutations in patients with advanced lung adenocarcinoma. We speculate that EGFR and ALK are more prone to concomitant mutations, respectively. Targeted therapies for patients with coexisting mutations need further study.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • RET mutation • ALK mutation • MET mutation • ROS1 mutation • EGFR mutation + PIK3CA mutation
5d
Patients received cyclophosphamide and fludarabine lymphodepletion, TIL infusion and interleukin-2, followed by maintenance nivolumab. Neoantigen-reactive T cell clonotypes increased and persisted in peripheral blood after treatment. Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer.
P1 data • Clinical Trial,Phase I • Journal • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
IL2 (Interleukin 2)
|
Opdivo (nivolumab) • fludarabine IV
5d
Our study showed that FGF11 functions as an oncogene in tumor NSCLC progression. miR-525-5p seems to negatively regulate FGF11 and the oncogenic role of FGF11 is dependent on the upregulation of HIF-1α. Our study suggests that targeting FGF11 and HIF-1α may serve as novel strategies for the treatment of NSCLC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression
5d
Patients in the high-risk group were more sensitive to chemotherapeutic drugs and molecular targeted drugs such as cisplatin, doxorubicin, gefitinib, and bosutinib (P < 0.0001). In addition, inhibition of COL5A2 and EPHB2 effectively suppressed the proliferation and migration of LUAD cells. The current study identified angiogenesis regulators as potential biomarkers and therapeutic targets for LUAD and may help to further optimize cancer therapy.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • EPHB2 (EPH Receptor B2) • CD4 (CD4 Molecule) • COL5A2 (Collagen Type V Alpha 2 Chain)
|
TMB-H
|
cisplatin • gefitinib • doxorubicin hydrochloride • Bosulif (bosutinib)
5d
Moreover, overexpression of IRS-1 accelerated the proliferation, colony formation, and migration rate of H1299, A549, and LTEP-a2 cells, which was contradicting to the knockdown results. Overall, this study uncovered a regulatory mechanism by which phycocyanin inhibited the growth of NSCLC cells via IRS-1/AKT pathway, laying the foundation for the potential target treatment of NSCLC.
Journal
|
IRS1 (Insulin Receptor Substrate 1)
5d
The results revealed CDK1, CCNB2, and CDC25A as the hub genes involved in LUAD carcinogenesis and development, which could be used as the potential biomarkers and targets for LUAD.
Journal
|
CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
5d
Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with manageable TRAEs and the trial continues to recruit participants. Trial registration ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC-Tabular View-ClinicalTrials.gov.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
CSF2 (Colony stimulating factor 2)
|
Tyvyt (sintilimab)
5d
Mammary gland adenoma was observed in the abdominal subcutaneous mass. This is the first report of primary three neoplasms of malignant melanoma, trichoblastoma and mammary gland adenoma in a Eurasian otter.
Journal
|
VIM (Vimentin)
5d
The simultaneous application of the K3.1 channel blocker senicapoc increases the sensitivity towards a low dose of erlotinib (300 nmol/L) which by itself has no effect on migration and proliferation. Our results suggest that K3.1 channel blockade may constitute a therapeutic concept for treating NSCLC and overcome EGFR TKI resistance. We propose that this is due to complementary mechanisms of action of both blockers.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
erlotinib • senicapoc (ICA-17043)
5d
In contrast, SCAL1 knockdown showed converse results for these assays. These results confirm the oncogenic function of SCAL1 and its role as a CSE-activated lncRNA that mediates ROS detoxification in A549 cells, thereby allowing them to develop resistance to and survive smoke-induced toxicity.
Journal
|
LUCAT1 (Lung Cancer Associated Transcript 1)
5d
Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective.
Clinical • Journal • Pan tumor
|
MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
MAP2K1 expression
5d
We found that EGFR mutations can be separated into four distinct subgroups on the basis of sensitivity and structural changes that retrospectively predict patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. Together, these data delineate a structure-based approach for defining functional groups of EGFR mutations that can effectively guide treatment and clinical trial choices for patients with EGFR-mutant NSCLC and suggest that a structure-function-based approach may improve the prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 18 mutation
5d
This study constructed a unique model for predicting the prognosis of lung cancer patients on the basis of four genes common to OSA and lung cancer. These genes may also serve as candidate genes to improve our knowledge about the underlying mechanism of OSA that leads to an increased risk of lung cancer at the genetic level.
Clinical • Journal
|
PDGFB (Platelet Derived Growth Factor Subunit B) • MAPK3 (Mitogen-Activated Protein Kinase 3)
5d
Hence, the tumour could be a primary small cell brain carcinoma. The patient underwent surgical resection again; the excised tumour was a mass of grey and white tissues with fragmentary morphology, and its dimensions were 3.0 cm×1.5 cm×0.8 cm.
Journal
|
NKX2-1 (NK2 Homeobox 1) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
5d
AlPcSCl's effectivity was demonstrated with CSC eradication showing a significant increase in cytotoxicity and cell death via apoptosis, caused by a decrease in mitochondrial membrane potential. PDT could serve as a palliative treatment for lung cancer and improve prognosis by elimination of lung CSCs.
Journal
|
CD133 • CD44 • NCAM1 (Neural cell adhesion molecule 1)
|
CD133 positive • CD33 positive
5d
This study did not find a prognostic difference with sex, smoking history, age, or p.G12C mutation. The patients in this cohort with KRAS p.G12C had a numerically lower 12-month overall survival in both early and advanced stage disease compared to other mutations, and over one-quarter had a notable history of previous and second primary malignancies.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
5d
Our study was limited by small sample size, retrospective nature and inability to control for confounders including prior bevacizumab or immune checkpoint inhibitor (ICI) exposure. This study offers real-world estimates to clinicians and patients about the length of time they can expect to derive benefit from the combination of ramucirumab and docetaxel.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • docetaxel • Cyramza (ramucirumab)
5d
NSCLC patients treated with nivolumab, pembrolizumab, or atezolizumab at Saitama Medical Center from January 1, 2016 to December 31, 2018 were enrolled, and followed until December 31, 2020. The MIC between IRP and TTF was 0.302 with weak correlation, and the Spearman's rank correlation coefficient was -0.347 (P=0.00938). The initial tumor growth rate had a negative linear correlation with the therapeutic effect of ICIs.
Clinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)
5d
Together, individualized genetic testing is a feasible and minimally invasive approach in cancer genetic analysis. However, gene mutation detection has a limited efficacy in the prediction of prognosis.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • NOTCH1 (Notch 1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
TP53 mutation • EGFR mutation • STK11 mutation
5d
The risk model participated in cytokinetic process, cell cycle, citrate cycle TCA cycle, etc. The risk model score was correlated with the levels of B cells memory, mast cells resting, macrophages M0, mast cells activated, neutrophils, eosinophils, T cells gamma delta, and immune cell markers. The risk model based on the LUAD brain metastasis immune factors TNFRSF11A, MS4A2, IL11, CAMP, MS4A1, and F2RL1 was related to the diagnosis, poor prognosis, and immune infiltrating cells of LUAD patients, and is expected to provide a reference for the development of treatment strategies for LUAD patients.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • MS4A1 (Membrane Spanning 4-Domains A1) • TNFRSF11A (TNF Receptor Superfamily Member 11a)
5d
2-arachidonoyl glycerol (2-AG) was increased in tumors of MGL KO mice, and dose-dependently induced differentiation and migration of CD8 T cells as well as migration and activation of eosinophils in vitro. Our results suggest that next to cancer cell-derived MGL, TME cells expressing MGL are responsible for maintaining a pro-tumorigenic environment in tumors of NSCLC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
5d
The sequential steps for invasion and metastasis were completed by an inverse association between functional barrier created by PD-L1 immunosuppressive molecule and EMT transcriptional factors. Our study implicates upregulation of EMT transcription factors to high proliferation rates, mechanical molecular barriers disassembly and increased cancer cell motility, as a critical molecular event leading to metastasis risk in PNENs thus emerging as a promising tool to select and customize therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CDH1 (Cadherin 1) • KRT14 (Keratin 14) • STEAP1 (STEAP Family Member 1) • CDH2 (Cadherin 2) • IL1RN (Interleukin 1 receptor antagonist) • SNAI2 (Snail Family Transcriptional Repressor 2) • COL5A2 (Collagen Type V Alpha 2 Chain)
5d
Therefore, our studies delineated the oncogenic role of CDC20 and its prognostic significance at the pan-cancer level and proved its functional activity in Cdc20 high expression cancer types. Our studies will merits further molecular assays to understand the potential role of Cdc20 in tumorigenesis and provide the rationale for developing novel therapeutic strategies.
Journal • Pan tumor
|
PLK1 (Polo Like Kinase 1) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
CDC20 overexpression
5d
When EGFR mutation is suspected, complete DNA sequencing of exons 18 to 21 should be carried out and we suggest that afatinib should be the first-line treatment for exon 18 delE709_T710insD-mutated advanced lung adenocarcinomas. Rare EGFR gene mutations are not detected by standard diagnostic kits.DNA sequencing is required to diagnose rare mutations of the EGFR gene.delE709_T710insD-mutated stage IV lung adenocarcinomas respond to afatinib.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 18 mutation • EGFR E709_T710delinsD • EGFR delE709_T710insD
|
Gilotrif (afatinib)
5d
Pulmonary mucous gland adenomas are rarely located peripherally. These benign tumors should be considered, even in the presence of high serum carcinoembryonic antigen concentrations or increased fluorodeoxyglucose uptake on fluorodeoxyglucose-positron emission tomography.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
5d
The FDA has approved the application of pembrolizumab for solid tumors with high microsatellite instability and defective mismatch repair, including cholangiocarcinoma. Moreover, the combination of ICIs with chemotherapy and radiation therapy showed good promise. The aim of the present study was to review the application of ICIs in the treatment of cholangiocarcinoma and to summarize the reported individualized immunotherapy-based protocols and ongoing clinical trials for clinical reference.
Journal • Checkpoint inhibition
|
MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
5d
In the meantime, should we treat patients with osimertinib as adjuvant therapy until the OS data is available? There is not an easy answer for this but most of us are in favor of giving osimertinib a chance until we have definitive data or better options to prevent recurrence and prolong DFS in our early-stage NSCLC patients.
Clinical • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R
|
erlotinib • Tagrisso (osimertinib) • gefitinib
5d
Treatment with FL3, a synthetic flavagline, sensitized A549Res cells to cisplatin. In conclusion, metformin could potentially be used as an adjuvant for cisplatin-based therapy in NSCLC cells if wild type P53 is present.
Journal
|
TP53 (Tumor protein P53) • ARID1B (AT-Rich Interaction Domain 1B)
|
TP53 expression
|
cisplatin • metformin
5d
Compared with NC group, overexpression of CacyBP inhibited E-cadherin expression while promoted the expressions of N-cadherin, Snail1, Vimentin and p-Akt, which could be restored by LY294002. CacyBP may promote the proliferation and invasion of NSCLC cells by regulating Akt signal pathway.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • S100A6 (S100 calcium binding protein A6)
|
CDH1 expression • VIM expression
|
quercetin (LY294002)
5d
The addition of thalidomide to pyrotinib is expected to increase the clinical benefit in advanced NSCLC patients with HER2 exon 20 insertions, and reduce the incidence of pyrotinib-related diarrhea. We believe thalidomide is the stone that can hit two birds.
Clinical • P2 data • Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CRBN (Cereblon) • IKZF1 (IKAROS Family Zinc Finger 1) • IKZF3 (IKAROS Family Zinc Finger 3)
|
HER-2 positive • EGFR mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation
|
Gilotrif (afatinib) • Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Irene (pyrotinib) • Vizimpro (dacomitinib) • thalidomide • poziotinib (HM 78136B)
5d
Our results indicate that miR-550a-3-5p and YAP1 may be novel potential targets for controlling brain metastasis.
Journal • PARP Biomarker
|
CDK6 (Cyclin-dependent kinase 6) • YAP1 (Yes associated protein 1) • CTGF (Connective tissue growth factor)
|
CDK6 expression
5d
Signet ring cell cytomorphologic characteristics of pulmonary adenocarcinoma are associated with the percentage of ALK-positive cells. Signet ring cell cytomorphologic characteristics and the percentage of ALK-positive cells might predict the prognosis of pulmonary adenocarcinoma with crizotinib treatment.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • ALK rearrangement
|
Xalkori (crizotinib)
5d
These findings demonstrate the antitumor immune responses mediated by macrophage activation on local administration of poly(I:C)+R848 combination and support the intratumoral application of this therapy to patients with solid tumors in the clinic.
Journal • Combination therapy
|
CD8 (cluster of differentiation 8) • CSF1 (Colony stimulating factor 1) • CD4 (CD4 Molecule) • MRC1 (Mannose Receptor C-Type 1) • FOXP3 (Forkhead Box P3)
|
Zyclara (imiquimod)
5d
This first WES analysis of pleomorphic mesotheliomas did not identify novel or unique mutations. In contrast to transitional mesothelioma that was reclassified as sarcomatoid variant based on transcriptome data, pleomorphic mesotheliomas are molecularly heterogeneous and therefore their reclassification into single subtype is more difficult.
Clinical • Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • NF2 (Neurofibromin 2)
|
TP53 mutation • CDKN2A deletion • PBRM1 mutation • NF2 mutation
5d
Moreover, invasion was also suppressed to 77% to 83% in TFF-1-transfected cells. These findings reveal that TFF-1 functions as a suppressor of cancer proliferation by induction of apoptosis, cell migration and invasion and thus may provide a synergistic target for potential treatment strategies for human lung carcinoma.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
5d
circPTCH1 plays a tumor enhancement role in lung cancer and that can effectively promote migration, invasion and EMT by targeting the miR-34c-5p/MYCN axis. circPTCH1 may be a novel potential treatment and diagnosis biomarker for lung cancer.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • PTCH1 (Patched 1)
5d
ONC201 activates the cellular integrated stress response and induces the TRAIL pro-apoptotic pathway. Combination treatment of lurbinectedin with ONC201 are currently being investigated in preclinical studies that may facilitate translation into clinical trials for SCLC patients.
Preclinical • Review • Journal • Combination therapy • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation • RB1 mutation + TP53 mutation
|
ONC201 • Zepzelca (lurbinectedin)
5d
In addition, high PARP1 expression was positively associated with microsatellite instability event in COAD, KIRP, BRCA, glioblastoma multiforme (GBM), lung squamous cell carcinoma (LUSC), LGG, READ, UCEC, SKCM and LUAD (P < 0.05). Our results highlight the significance of PARP1 alterations as pan-cancer predictive biomarkers for ICI treatment, and its expression levels seem to be correlated with the status of immunotherapy-associated signatures, thus may be a promising biomarker for predicting ICI response in several tumors.
Journal • Tumor Mutational Burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • TMB-H • LAG3 expression • CTLA4 expression • PARP1 overexpression
5d
Further, PD-1 inhibition upregulates pulmonary ILC2-derived TNF-α production, a cytotoxic cytokine that directly induces cell death in B16 cells, independent of adaptive immunity. Together, these results highlight the importance of ILC2s and their anti-tumor role in pulmonary B16 cancer progression during PD-1 inhibitory immunotherapy.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
5d
In addition, HVEM seems to be involved in tumor immuno-evasion, especially in lung tumors lacking PD-L1 expression. Here, we propose to review the role of BTLA-HVEM in immuno-escape in order to highlight its potential for designing new immunotherapies.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BTLA (B And T Lymphocyte Associated)
|
PD-L1 expression
5d
A serial increase (pre- to post-surgery to ICI initiation) of C-reactive protein (CRP) and prognostic nutritional index (PNI) was associated with treatment response (both P=0.01). These results suggest that a response to ICI monotherapy significantly contributes to a survival benefit regardless of therapeutic lines in NSCLC patients with recurrence after completely pulmonary resection, and the therapeutic response is strongly associated with a serial increase in CRP or decrease in prognostic nutritional index.
Clinical • Journal • Checkpoint inhibition
|
CRP (C-reactive protein)
5d
In vivo experiments in nude mice showed that knockdown of LINC00115 could significantly inhibit the proliferation of lung cancer tissues in vivo. LINC00115 is highly expressed in lung cancer tissues, and knockdown of LINC00115 can significantly inhibit the proliferation and invasion of lung cancer, which provides a theoretical basis for the design of targeted molecules for the subsequent treatment of lung cancer.
Preclinical • Journal
|
CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • VIM (Vimentin)
|
CDH1 expression • VIM expression
5d
FANCI may be a key gene to the determine metastasis and poor prognosis in patients with LUAD. Changes in the immune microenvironment may be the mechanism through which FANCI leads to poor prognosis of LUAD.
Journal
|
FANCI (FA Complementation Group I) • MIR218 (MicroRNA 218)
5d
Based on the identified tumor metabolism-immune landscape, we were able to predict a metabolism risk score for patient prognosis and identify a correlation with two types of infiltrating lymphocytes in the TME of p53-mutated LUAD. This landscape provides insights that will help identify the molecular mechanisms of immune-editing tumor metabolism.
Clinical • Journal • Tumor-Infiltrating Lymphocyte
|
TP53 (Tumor protein P53) • CD4 (CD4 Molecule) • ALDH3A1 (Aldehyde Dehydrogenase 3 Family Member A1)
|
TP53 mutation
5d
The prognosis of EGFR-TKI treatment may vary according to different BRAF actionable mutations. Aside from BRAF V600E, class II/III and BRAF fusions were found, which provides clues for investigating the resistance mechanisms of EGFR-TKIs in the future.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53)
|
TP53 mutation • BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • EGFR T790M • EGFR exon 19 deletion • MET exon 14 mutation • MET mutation • BRAF fusion • BRAF mutation + EGFR mutation
5d
These findings reinforce the patient benefit observed with durvalumab in unresectable stage III NSCLC, support the routine use and cost effectiveness of this therapy, and demonstrate how appropriate modelling can inform the early adoption of therapies by payers to achieve patient benefit.
Journal • HEOR
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab)
5d
Besides, intrinsic apoptotic pathway was supported by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of proapoptotic protein Bax. Molecular docking study for compounds 2b, 2c, and 2g was promoted experimental outcomes.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
5d
miR-128-3p repressed SKA3 expression by targeting it. miR-128-3p inhibited the progression of NSCLC through targeting SKA3.
Journal
|
MIR128 (MicroRNA 128)
5d
The relative bioavailability of the TSN to EA was 458.39%. The NM-loaded TSN is a supramolecular vesicle that can be produced at an industrial scale for efficient cancer therapy.
Clinical • Journal
|
CD133 • CD44
5d
This study demonstrates that USP52 inhibits cancer cell proliferation through downregulation of cyclin D1 as well as AKT/mTOR signaling pathway inhibition. Meanwhile, USP25 also suppresses NSCLC progression via enhancing PTEN stability in cancer cells, which further indicates the significance/importance of USP52 in NSCLC suppression.
Journal
|
PTEN (Phosphatase and tensin homolog) • CCND1 (Cyclin D1)
5d
Although some anti-cancer treatments might alter the TROP2 expression, TROP2 was expressed in most lung cancer specimens before and after anti-cancer treatments. These results support the development of TROP2-directed therapy against advanced lung cancer in various treatment lines.
Clinical • Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression
5d
Rates of resistance mutation testing and subsequent utilization of recommended 2L therapies could be improved. As more targeted therapies are developed, it will be crucial to improve the molecular testing rates to ensure patients receive appropriate, effective, and timely treatment.
Retrospective data • Review • Journal • HEOR • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
5d
Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5d
Analysis of human samples and sequencing datasets revealed that CCR6 TCF1 cells exist across human cancers and are not correlated with ICB response. Vaccination eliminated CCR6 TCF1 cells and dramatically improved the subdominant response, highlighting a strategy to optimally engage concurrent neoantigen responses against tumors.
Journal
|
CD8 (cluster of differentiation 8) • CCR6 (C-C Motif Chemokine Receptor 6)
5d
We identified novel adaptive resistance, generated through c-Jun N-terminal kinase (JNK)/c-Jun signaling, to initial ALK-TKIs-alectinib and brigatinib-in ALK-rearranged NSCLC. Importantly, combination therapy targeting JNK and ALK significantly delayed the regrowth following cessation of these treatments. Together, our results demonstrated that JNK pathway activation plays a pivotal role in the intrinsic resistance to ALK-TKIs and the emergence of ALK-TKI-tolerant cells in ALK-rearranged NSCLC, thus indicating that optimal inhibition of tolerant signals combined with ALK-TKIs may potentially improve the outcome of ALK-rearranged NSCLC.
Journal
|
ALK (Anaplastic lymphoma kinase) • BCL2L1 (BCL2-like 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
ALK rearrangement
|
Alecensa (alectinib) • Alunbrig (brigatinib)
5d
We validated the new molecular subtype classification in primary SCLC tumors by IHC and identified several intriguing associations between subtypes and therapeutic markers. The new subtype classification may potentially assist treatment decisions in SCLC.
Journal
|
CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • SYP (Synaptophysin)
5d
To resolve the problem of drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno [3,2-c]pyridine side chains (according to the binding mode of AZD9291 to EGFR) for use as EGFR kinase inhibitors...Moreover, compound A12 showed strong anti-proliferative activity against H1975 cells, with IC value of 0.086 μΜ. Additionally, the effective inhibition of cell migration and the promotion of apoptosis by A12 verified its mechanism of action, as a selective inhibitor of EGFR.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR H1975
|
Tagrisso (osimertinib)
5d
False positive ROS1 immunoreactivity was very frequent, occurred more commonly in primary NSCLC cases with acinar and/or lepidic histologies and was more likely in EGFR mutated cases. Using higher positivity thresholds for ROS1 IHC and incorporating the histologic and molecular correlates into algorithmic strategies could result in increased specificity and clinical utility of ROS1 IHC assay.
Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ROS1 positive • ROS1 rearrangement
6d
PathAI pretrained algorithms generated PD-L1 22C3 scores for WSI scanned on 2 separate platforms that were highly correlative to manual scores. This study demonstrates the feasibility of generalized, automated derivation of accurate scores from a diverse dataset of clinical images. Application of ML-based approaches has the potential to improve efficiency in pathology workflows and clinical decision-making.
Clinical • Real-world evidence
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
6d
In conclusion, it is crucial to exclude metastasis and Merkel cell carcinoma in cases with histomorphologic features of neuroendocrine carcinoma in breast biopsy specimens. Clinical-radiologic correlation and a limited panel of immunostains might help to establish the correct diagnosis (Figure 3.63, A and B, hematoxylin-eosin; C, synaptophysin; and D, TTF-1).
NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin)
|
NKX2-1 expression
6d
Pulmonary NUT carcinoma should be suspected in all squamous cell carcinoma with unusual features, particularly in a nonsmoker and a young patient. We hereby report this case because the cytologic features of NUT carcinoma have been rarely documented and those of a primary NUT carcinoma of the lung with BRD3-NUTM1 fusion have never been reported.
Endobronchial ultrasound
|
NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • BRD4 (Bromodomain Containing 4) • TP63 (Tumor protein 63) • NUTM1 (NUT Midline Carcinoma Family Member 1)
6d
These findings are consistent with intraosseous hibernoma with lytic changes. Although rare, recognition of this benign entity is critical, as its radiographic findings may suggest a malignant process.
CD163 (CD163 Molecule) • SOX10 (SRY-Box 10) • SDC1 (Syndecan 1) • CD68 (CD68 Molecule)
6d
The overall performance of immunohistochemistry on this case would have been quite suggestive of PEComa, but because of the uncommon nature may not have been diagnosed on cytology without the previous diagnosis. Given the differences in treatment and prognosis, the need to routinely perform myomelanocytic markers on primary cytology of high-grade mesenchymal gynecologic neoplasms is suggested, especially in cases where smooth muscle markers are positive.
SOX10 (SRY-Box 10)
6d
After the US Food and Drug Administration approval of Larotrectinib, the detection of NTRK fusion in many late-stage cancers have become a standard part of management... We expand the list of tumors that may be positive for NTRK fusion protein by IHC. The high diagnostic sensitivity, cost-effectiveness, and rapid turnaround time, the monoclonal antibody (EPR17341) may potentially be used as a screening marker to rule in NTRK positive tumors especially when DNA or RNA-based molecular testing is not available.
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • ETV6-NTRK3 fusion • NTRK fusion • NTRK positive
|
VENTANA pan-TRK (EPR17341) Assay
|
Vitrakvi (larotrectinib)
6d
SMARCA4-deficient lung tumors tend to behave more aggressively and have a poorer prognosis than SMARCA4 retained lung tumors and should be considered when working up a poorly differentiated brain mass, especially in a patient with a pulmonary/thoracic mass. Summary of Immunohistochemistry Panel View largeView Large
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
6d
Distinguishing PMCS from metastatic mucinous carcinoma of breast can be challenging. Therefore, radiologic and clinical correlation is important (Figure 4.24).
NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
6d
MP and non-MP portions can have similar genetic alterations and such tumors may pursue a nonaggressive clinical course. Prolonged tumor growth accumulates genetic damage, and the extent can be striking. Findings of our cohort support literature and the molecular data obtained with a 13-year interval offered a rare chance to gain insights on tumor evolution.
Clinical
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • KMT2D (Lysine Methyltransferase 2D)
|
MET exon 14 mutation
6d
In contrast to usual MSCGP, this tumor was peripherally located and directly extended into the adjacent alveolar spaces. Future studies are necessary to explore the pathogenesis of these lesions.
Clinical
|
NKX2-1 (NK2 Homeobox 1)
6d
Patient received right wedge resection of middle lobe and right upper lobectomy. The rarity glomus tumors in lung makes this a challenging diagnosis, immunohistochemistry with histologic correlation can aid in accurate diagnosis (Figure 4.105).
NKX2-1 (NK2 Homeobox 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SOX10 (SRY-Box 10) • CDX-2 • SDC1 (Syndecan 1) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • NKX3-1 (NK3 homeobox 1) • SYP (Synaptophysin)
6d
However, GATA-3 positivity concurrently with TTF-1 negativity is rather uncommon. Therefore, our case emphasizes the importance of considering TTF1-negative, GATA3-positive lung adenocarcinoma for pulmonary masses with diagnostically challenging immunohistochemistry profiles.
Clinical • Review
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin)
|
HER-2 negative • NKX2-1 expression
6d
The patient had received high-dose corticosteroids, tacrolimus, mycophenolate, and valacyclovir therapies, and had no lupus flares...These findings are consistent with EBV-associated smooth muscle tumors. EBV-associated smooth muscle tumors although rare, may occur with diffuse pattern of pulmonary involvement and should be considered in patients with solid organ transplant and incidental findings of multiple organ lesions on imaging.
Clinical
|
SOX10 (SRY-Box 10)
|
valacyclovir
6d
Although adenomatoid tumor was considered, the lack of a mass lesion was most consistent with unusual mesothelial inclusions rather than a neoplasm (Figure 2.44, A, hematoxylin-eosin; B, Calretinin; C, WT1; D, PAX8, ×400 magnification). This is a rare case of unusual ovarian mesothelial inclusions not associated with endometriosis presenting as histologic mimickers of neoplasia.
Clinical
|
WT1 (WT1 Transcription Factor) • PAX8 (Paired box 8)
6d
The association of sarcomatoid features in SCCB is extremely rare, with few cases recorded in literature. The sarcomatoid components described in literature are nonspecific malignant spindle cells, chondrosarcoma, myxoid sarcomatous, osteosarcoma, and rhabdomyosarcoma (Figure 1.95).
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • NKX2-1 (NK2 Homeobox 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin)
6d
Yolk sac tumor should be considered in the differential diagnosis of a high-grade urothelial carcinoma, particularly when glandular or other unusual architectural patterns are present. A somatic origin with underlying genomic instability similar to what has been described in uterus and ovaries is suggested (PMID: 32558949).
GPC3 (Glypican 3) • NKX2-1 (NK2 Homeobox 1) • POU5F1 (POU Class 5 Homeobox 1) • CDX-2 • SALL4 (Spalt Like Transcription Factor 4) • PAX2 (Paired Box 2) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • NKX3-1 (NK3 homeobox 1)
6d
Furthermore, it may spur investigation among other recipients of organs from the same donor. Awareness of this largely nonpreventable complication and prompt implementation of molecular testing if cancer transmission is suspected are critical for proper management of these patients.
Clinical
|
NKX2-1 (NK2 Homeobox 1)
7d
Clinical • Enrollment change
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
7d
Clinical • Enrollment closed • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Imfinzi (durvalumab) • tremelimumab (CP-675206)
7d
P1, N=80, Recruiting, Syros Pharmaceuticals | Trial completion date: Jan 2023 --> Jul 2024 | Trial primary completion date: Jun 2021 --> Jul 2023
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
fulvestrant • SY-5609
7d
P2, N=23, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | N=60 --> 23 | Trial primary completion date: Dec 2021 --> Jul 2021
Clinical • Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
PD-L1 expression • EGFR mutation • EGFR T790M
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
7d
P=N/A, N=2400, Not yet recruiting, The Walter and Eliza Hall Institute for Medical Research
Clinical • Clinical data • New trial
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
7d
Clinical • New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
7d
In addition, we compared the OS rate between patients receiving atezolizumab and docetaxel classified according to their risk score based on our gene mutation signature model. The 5-genomic mutation signature could predict OS benefit for patients with NSCLC receiving atezolizumab. Therefore, the establishment of the 5-genomic mutation panel will guide clinicians to identify optimal patients who could benefit from atezolizumab treatment.
Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • CREBBP (CREB binding protein) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
PD-L1 expression • TP53 mutation • STK11 mutation • KEAP1 mutation • 5-genomic mutation signature
|
Tecentriq (atezolizumab) • docetaxel
7d
Our results suggest that compared with chemotherapy, icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection.
Clinical • P3 data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
cisplatin • pemetrexed • Conmana (icotinib) • vinorelbine tartrate
7d
Additional findings included a partial reduction of the increase in spleen-circulating biomarkers, a decrease in C-reactive protein and complement C3 in the spleen and lymph nodes, and an increase in lymph node purine nucleoside phosphorylase previously associated with liver immunodeficiency. Our results suggest some protein abundance changes could be related to the systemic, distant non-target antitumor effects produced by this phytochemical.
Preclinical • Journal
|
CRP (C-reactive protein)
7d
In the A549 tumor xenograft mouse model, we, for the first time, showed that BoHV-1 can infect tumor and suppressed tumor growth with a similar high efficacy as the treatment of TSA, and HDACs have potential effects on the virus replication. Taken together, our study demonstrates that BoHV-1 has oncolytic effects against human lung adenocarcinoma in vivo.
Journal
|
HDAC1 (Histone Deacetylase 1)
7d
This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed..
Clinical • Review • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK mutation
|
Alecensa (alectinib)
7d
Entrectinib, based on three clinical studies (ALKA, STARTRK-1, and STARTRK-2), was well tolerated, with a manageable safety profile. It induced clinically meaningful responses in recurrent or advanced solid tumors associated with NTRK fusion-positive or ROS1+ NSCLC. It demonstrated substantial efficacy in patients with CNS metastases.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 positive • NTRK fusion • NTRK positive
|
Rozlytrek (entrectinib)
7d
Immune reconstitution inflammatory syndrome may be potential mechanism of IRP. This study may improve our understanding of the pathogenesis underlying IRP. We believe the detection and dynamic monitoring CD4, CD8 T lymphocytes, MDSC and Treg cells can provide more accurate procedures.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
cisplatin • pemetrexed • trimethoprim/sulfamethoxazole
7d
Our findings expand on the SEER data and provide additional evidence suggesting improvements in survival of patients with advanced and metastatic NSCLC over the past decade could be explained by the change in treatment patterns over this period.
Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ROS1 positive
7d
The recombinant human MG53 (rhMG53) protein can enter the NSCLC cells to induce nuclear translation of G3BP2 and block arsenic trioxide-induced SG formation...rhMG53 can enhance sensitivity of NSCLC cells to undergo cell death upon treatment with cisplatin. Tailored induction of MG53 expression in NSCLC cells suppresses lung cancer growth via reduced SG formation in a xenograft model. Overall, these findings support the notion that MG53 functions as a tumor suppressor by targeting G3BP2/SG activity in NSCLCs.
Journal
|
G3BP2 (G3BP Stress Granule Assembly Factor 2)
|
cisplatin • arsenic trioxide
7d
We conclude that G:C > T:A mutations at KRAS codon 12 in the tumours of lung cancer patients (who smoke), proposed to be predominantly caused by BPDE, are due to the effect of the interaction methyl group at the C5 position of the thymine base in the KRAS sequence with the BPDE carcinogen investigated causing increased distortion. We further suggest methylated cytosine would have a similar effect, showing the importance of methylation in cancer development.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation
7d
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
7d
Although we have achieved diversity and identification of specific bacterial species, analysis of bacterial metabolites will be important in the future when considering the impact of the intestinal microbiota on immune cells. The gut microbiota is not only a biomarker for the treatment of ICIs, but also has the potential to create an immune state that facilitates the effects of ICI by changing the gut environment and metabolites.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
7d
A higher TMB per cluster is associated with better disease-free survival while single-nucleotide variant ITH is linked to worse overall survival, and therefore these features may be used as prognostic biomarkers for SCLC. Together, these findings demonstrate the intratumoral genetic heterogeneity of surgically resected SCLC and provide insights into resistance to treatment.
Journal • Tumor Mutational Burden
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation • TMB-H • EGFR mutation
7d
The results of CCK8 test and qRT-PCR showed that ginseng leaves inhibit cell proliferation and regulates AKT1 and P53 expression in A549. The present study clarifies the mechanism of Ginseng leaves against lung cancer and provides evidence to support its clinical use.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MAPK1 (Mitogen-activated protein kinase 1)
|
TP53 expression
7d
Oleanolic acid inhibited AKR1B10 activity and expression in Hep-2 cells and suppressed Hep-2 cell proliferation, migration, and invasion. Therefore, AKR1B10 may be related to the development of laryngeal carcinoma, suggesting its use as a prognostic indicator for laryngeal cancer.
Journal
|
TP53 (Tumor protein P53) • MMP2 (Matrix metallopeptidase 2)
|
TP53 mutation
7d
Additionally, the predictive model (CEA+SCCA+CY21-1+HE4) had better idea capability to detecting the existence of NSCLC (AUC=0.954, 95% CI=0.927-0.999, P<0.001). Our study showed that several lung cancer-related biomarkers were used to build prediction models, which has good value for early prediction of NSCLC.
Clinical • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • KRT19 (Keratin 19)
7d
At the same time, the combination of EpCAM/CD3 BsAb and MUC-1/CD3 BsAb significantly regulated T population in the TDLNs. Therefore, we have found a potential immunotherapeutic strategy, which was the combination therapy with EpCAM/CD3 BsAb and MUC-1/CD3 BsAb for the treatment of non-small cell lung cancer.
Journal • Combination therapy
|
MUC1 (Mucin 1) • EPCAM (Epithelial cell adhesion molecule)
7d
Furthermore, upon targeting PLK1, tumor cells that had undergone ICD were converted into an endogenous vaccine, which triggered the immune memory responses and protected the mice from tumor challenge. Collectively, these results suggested that the PLK1 inhibitor might function as an immune modulator in antitumor treatment.
Journal
|
PLK1 (Polo Like Kinase 1)
7d
We then showed that Tra2β was important for the localized protein expression mediated by GSN 3'UTR. Taken together, our results suggested that GSN 3'UTR may exert anticancer functions in NSCLC cells through regulating the subcellular localized expression of GSN protein mediated by the interaction between GSN 3'UTR-Tra2β.
Journal
|
GSN (Gelsolin)
7d
Furthermore, a significant association between this variant and nicotine dependence (OR: 2.27; 95% CI: 1.52-3.39; p = 0.00005) was reported. However, no association was found for rs3842A > G. The results suggested that the CHRNA3 rs1051730C > T via a smoking-dependent manner could modify susceptibility to lung cancer among Iranian population.
Clinical • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
7d
In this work, an ECL-RET biosensor comprising graphitic carbon nitride quantum dots was assessed for the amplification-free detection in the blood plasma of DNA molecules coding for the EGFR L858R mutation, which is associated with non-small-cell lung cancer. Following a low-cost pre-treatment, the highly specific ECL-RET biosensor quantified double-stranded EGFR L858R DNA of 159 nucleotides diluted into the blood within a linear range of 0.01 fM to 1 pM, demonstrating its potential for noninvasive biopsies.
Journal • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R
7d
An analysis of sera from patients revealed that serum seCad is associated with distant metastasis. Our data suggest that senescent cells promote metastatic lung cancer through seCad, and that seCad may be a potential diagnostic marker as well as a therapeutic target for metastatic lung cancer.
Journal
|
CDH1 (Cadherin 1)
7d
This study aimed to prepare arginyl-glycyl-aspartic acid (RGD) containing nanostructured lipid carrier (NLC-RGD) to improve the bioavailability of galangin and explore its ability in improving the cytotoxic effects of doxorubicin (DOX)...Gene expression analysis demonstrated that galangin-loaded NLC-RGD downregulates ABCB1, ABCC1, and ABCC2 more efficiently than galangin. These findings indicated that delivery of galangin by NLC-RGD makes it an effective adjuvant to increase the efficacy of chemotherapeutic agents in cancer treatment.
Clinical • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC2 • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
doxorubicin hydrochloride
7d
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
7d
Satellite CME Symposium by Research To Practice. No abstract available for this presentation
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 positive
7d
Introduction For patients with unresectable stage III non-small cell lung cancer (NSCLC), the standard of care is concurrent chemoradiotherapy (CRT), and the PACIFIC trail demonstrated significant progression-free survival (PFS) and overall survival (OS) benefit with the consolidation durvalumab for those without progression...In group B, radiotherapy (total dose 54-66 Gy, once daily, 5 times a week) in combination with cisplatin (75 mg/m2) plus pemetrexed (500 mg/m2) on day 1 of 21-day cycles (every 3 weeks) will be given for 3 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks for 4 cycles...Planned total treatment duration is 24 months. The first patient had been enrolled in March 2021.
PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
cisplatin • Imfinzi (durvalumab) • pemetrexed • Ameile (almonertinib)
7d
Industry Symposium Sponsored by Amgen.No abstract available for this presentation
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
7d
Our findings identified that inhibition of circ_0058357 suppresses the growth and metastasis of H1299/DDP and A549/DDP cells and sensitizes them to DDP therapy partially by targeting the miR-361-3p/ABCC1 axis.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MIR361 (MicroRNA 361)
|
ABCC1 expression
|
cisplatin
7d
Furthermore, associations of urinary ∑OH-Nap and ∑OH-PAHs levels with lung cancer risk were modified by XRCC1 rs25487 (P ≤ 0.025), and were more pronounced in wild-types of rs25487. These findings suggest that environmental exposure to naphthalene and phenanthrene is associated with increased lung cancer risk, and polymorphism of XRCC1 rs25487 might modify the naphthalene exposure-related lung cancer effect.
Clinical • Journal
|
XRCC1 (X-Ray Repair Cross Complementing 1)
7d
Importantly, BRPS significantly suppressed the growth of LLC cells in vivo without any obvious side effect on body weight and organs of mice, and increased the proportion of B cells, CD4 T cells, CD8 T cells and CD44CD8 T cells in the spleen. These results revealed that BRPS inhibited the growth of lung cancer cells through inducing cell cycle arrest, mitochondria-dependent apoptosis, and activating immunity of mice, and BRPS might be a potential anti-tumor functional food and promising agent for the treatment of lung cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BAX (BCL2-associated X protein) • CD44 • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP9 (Caspase 9) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
7d
The results of the dual-luciferase reporter assay and western blotting indicated that miR-487a-3p antagomir exerted antitumor effects via targeting Smad7. The findings of the present study revealed that downregulation of miR-487a-3p suppressed the progression of NSCLC via inhibiting the Smads pathway, and it may serve as a novel promising target for the treatment of NSCLC.
Journal
|
SMAD7 (SMAD Family Member 7)
7d
Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET inhibitor. More than one-third of patients reported a reduction in dyspnea during study participation and nearly half reported a reduction in pain by the first-follow up assessment.
Clinical • P1/2 data • Journal • Patient reported outcomes
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
7d
The linear model was built to predict the tumor volume nadir in EGFR-mutant advanced NSCLC patients treated with EGFR-TKIs, which provide an important metrics in treatment monitoring and therapeutic decisions at nadir such as additional local abrasive therapy.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
7d
Our findings suggest that SRGN plays a pivotal role in tumor-stromal interaction and reprogramming into an aggressive and immunosuppressive tumor microenvironment in TTF-1-negative LUAD.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NKX2-1 (NK2 Homeobox 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • NNMT (Nicotinamide N-Methyltransferase)
|
PD-L1 expression • PD-L1 overexpression • NKX2-1 expression
7d
IT approaches available thus far in NSCLC, mainly represented by anti-PD-1/PD-L1 inhibitors, are not promising in the case of STK11 inactivation. Perceptive strategies aimed at modulating the TIME, regardless of STK11 status or specifically addressed to STK11-mutated cases, will hopefully provide valid therapeutic options to be adopted in the clinical practice.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • KRAS mutation • STK11 mutation
7d
Importantly, ROS blockade, autophagy inhibition or TRAF6 knockdown abolished PM-induced neutrophil recruitment and lung metastasis enhancement. Our study indicates that host lung epithelial cells and neutrophils coordinate to promote cancer metastasis to the lungs in response to PM exposure and provides ideal therapeutic targets for metastatic progression.Abbreviations: ACTA2/α-SMA: actin alpha 2, smooth muscle, aorta; ATII: alveolar type II; Cho-Traf6 siRNA: 5'-cholesterol-Traf6 siRNA; EMT: epithelial-mesenchymal transition; HBE: human bronchial epithelial; HCQ: hydroxychloroquine; MAPK: mitogen-activated protein kinase; NAC: N-acetyl-L-cysteine; NFKB: nuclear factor of kappa light polypeptide gene enhancer in B cells; NS: normal saline; PM: particulate matter; ROS: reactive oxygen species; TRAF6: TNF receptor-associated factor 6; TRIM37: tripartite motif-containing 37.
Journal
|
ACTA2 (Actin Alpha 2 Smooth Muscle) • TRIM3 (Tripartite Motif Containing 3)
|
hydroxychloroquine
7d
We found that patients who benefited from first-line EGFR-TKIs may experience prolonged PFS and a higher response rate when subsequently given osimertinib. A low plasma frequency of the EGFR T790M allele may predict poor osimertinib efficacy and shorter PFS.
Clinical • Clinical data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
7d
P1, N=219, Active, not recruiting, Infinity Pharmaceuticals, Inc. | Trial completion date: Jun 2021 --> Oct 2022 | Trial primary completion date: Jun 2021 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • ER negative • PGR negative
|
Opdivo (nivolumab) • eganelisib (IPI-549)
7d
P2, N=33, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
EGFR mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
7d
P1/2, N=150, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2021 --> Jan 2022
Clinical • Enrollment closed • Trial primary completion date • Pan tumor
|
TMB (Tumor Mutational Burden)
|
Imfinzi (durvalumab) • tremelimumab (CP-675206) • Navelbine oral (vinorelbine tartrate oral)
8d
P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2022
Clinical • Enrollment closed • Trial completion date
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
|
zeteletinib (BOS-172738)
8d
Clinical • Trial primary completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
docetaxel • tusamitamab ravtansine (SAR408701)
8d
P1, N=136, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
EGFR mutation • EML4-ALK fusion • ALK fusion
|
cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
8d
P1, N=60, Recruiting, Pacylex Pharmaceuticals | Trial completion date: Dec 2022 --> Mar 2023
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
PCLX-001
8d
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Hyleukin-7 (efineptakin alfa)
8d
Clinical • New P2 trial • IO biomarker
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
carboplatin • paclitaxel
8d
New trial
|
B2M (Beta-2-microglobulin) • CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC1 (Mucin 1) • KRT19 (Keratin 19) • CRP (C-reactive protein)
8d
New P2 trial • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
FoundationOne® CDx • Guardant360® CDx • cobas® EGFR Mutation Test v2 • therascreen® EGFR RGQ PCR Kit
|
Cyramza (ramucirumab) • poziotinib (HM 78136B)
8d
We found that after a long-term exposure to gefitinib, the first-generation EGFR-TKI lung cancer cells harboring the EGFR-TKI-sensitive mutations became resistant to both gefitinib and osimertinib. Finally, MSI2 knockdown greatly increased the sensitivity to osimertinib in vivo. Collectively, our findings provide proof of principle that targeting the MSI2-Nanog axis in combination with EGFR-TKIs would effectively prevent the emergence of acquired resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • MSI2 (Musashi RNA Binding Protein 2) • NANOG (Nanog Homeobox)
|
EGFR mutation • EGFR expression • MSI2 overexpression
|
Tagrisso (osimertinib) • gefitinib
8d
Furthermore, in the mouse model of LMC with resistant cells, combined osimertinib and trametinib treatment successfully controlled LMC progression. These findings suggest a potential novel therapy against KRAS-G12V-harboring osimertinib-resistant LMC in EGFR-mutant NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • EGFR exon 19 deletion • KRAS G12V • KRAS G12 • KRAS overexpression • KRAS deletion
|
Mekinist (trametinib) • Tagrisso (osimertinib)
8d
Several clinical trials have demonstrated that ALK-inhibitors (crizotinib, alectinib, brigatinib) show excellent activity also against brain metastases. It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.
Review • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK translocation
|
Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)
8d
Of note, hybrid 3 also had a significantly lower cytotoxic effect on healthy human lung epithelial cells (BEAS-2B) than 5-FU. Altogether our results served as an initial proof-of-concept to develop 5-FU/HO-1 mutual prodrugs as potential novel anticancer agents.
Preclinical • Journal
|
HMOX1 (Heme Oxygenase 1)
|
5-fluorouracil
8d
Among patients with high PD-L1 expression undergoing first-line pembrolizumab monotherapy for NSCLC, PPS was more strongly correlated with OS, relative to the relationship between PFS and OS. Therefore, subsequent treatment appears to significantly influence OS in patients with disease progression following first-line pembrolizumab monotherapy.
Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab)
8d
Lower Rova-T doses may be associated with lower incidence of some Rova-T-related AESI. Rova-T 0.2 mg/kg + CE (Cohort 3) was tolerable; however, there was no clear efficacy benefit of adding Rova-T to CE.
Clinical • P1 data • Clinical Trial,Phase I • Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
cisplatin • carboplatin • etoposide IV • Rova-T (rovalpituzumab tesirine)
8d
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8d
Clinical • Journal
|
STK11 (Serine/threonine kinase 11) • MIR17 (MicroRNA 17)
|
STK11 expression
8d
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8d
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8d
EphB4 is associated with the EGFR-independent suppressive effects of osimertinib on cell cycle and with a poor clinical outcome. Osimertinib can exert significant growth inhibitory effects in EGFR-mutated NSCLC patients with a high EphB4 status.
Journal
|
EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • EPHB4 (EPH receptor B4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
EGFR mutation • EGFR expression • CCND1 expression
|
Tagrisso (osimertinib)
8d
By mining existing sequencing data, we further demonstrate that the expression levels of TNF and TACE are significantly decreased in lung adenocarcinoma patients, while the TNFR1/TNFR2 balance are increased. We conclude that the biomarker potential of TNFα alone will most likely not provide conclusive findings, but that TACE could have a key role along with the delicate balance of sTNFα/tmTNFα as well as TNFR1/TNFR2, hence stressing the importance of more research into the potential of rationalized treatments that combine TNFα pathway modulators with immunotherapy for lung cancer patients.
Review • Journal • Checkpoint inhibition • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • ADAM17 (ADAM Metallopeptidase Domain 17) • TNFRSF1B (Tumor necrosis factor receptor superfamily member 1B)
8d
Cellular senescence elimination was associated with p53/p21 and p16/pRb signaling inactivation. Paclitaxel may be a promising anticancer drug and offer a new therapeutic strategy for managing gefitinib-resistant NSCLC during the COVID-19 pandemic.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
gefitinib • paclitaxel
8d
"KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation."
Journal
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • TP53 mutation • KRAS mutation • TMB-H • KRAS G12C • KRAS G12D • STK11 mutation • KRAS G12V • KRAS G13 • KRAS G12 • KRAS expression
|
PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™
8d
The constructed prognostic model can predict overall survival in LUAD patients with great predictive performance, and it may be applied for diagnosis and adjuvant treatment of LUAD in clinical trials.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
PD-1 expression • PD-1-H
8d
HDAC6 expression can predict the prognosis of NSCLC patients who were treated with ICIs. Furthermore, co-treatment with HDACi and PD-1 inhibitor was shown to decrease the tumor growth rate and create a favorable tumor microenvironment for cytotoxic T lymphocytes in the TC-1 mouse model.
Journal • PD(L)-1 Biomarker • IO biomarker • Epigenetic controller
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • HDAC6 (Histone Deacetylase 6) • IL1B (Interleukin 1, beta)
|
PD-L1 expression • CD8 expression • IL6 expression
8d
1. Expression of DPYSL2 was considerably lower in LUAD than in normal tissues. 2. Investigation of multiple databases showed a high diagnostic value of DPYSL2 in LUAD. 3. DPYSL2 can independently predict the LUAD outcomes. 4. Immune-related mechanisms may be potential ways for DPYSL2 to play a role in LUAD.
Journal • IO biomarker
|
CD4 (CD4 Molecule)
8d
This randomized clinical trial suggested that TEA could attenuate local inflammatory responses in the lungs during lung cancer surgery.
Clinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
Chirocaine (levobupivacaine) • fentanyl citrate • remifentanil • rocuronium
8d
The present review therefore aimed to synthesize our current understanding of the tumor immune microenvironment in MPM and reflects on how specific cellular features might impact immunotherapy responses or lead to resistance. This approach will inform stratified approaches to therapy and advance immunotherapy combinations in MPM to improve clinical outcomes further.
Clinical • Review • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB-L
8d
The OX40 pathway is expressed in a fraction of NSCLCs and is associated with a favorable immune contexture. Although OX40L is uncommonly expressed in NSCLC and serous malignancies, it is associated with better prognosis and can be introduced using exogenous mRNA.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
KRAS mutation • EGFR mutation • TNFRSF4 expression
|
mRNA-2416
8d
Reactivation of SMARCA2 by a histone deacetylase inhibitor rescues IP3R3 expression and enhances cisplatin response in SMARCA4/2-deficient cancer cells both in vitro and in vivo. Our findings elucidate the contribution of SMARCA4/2 to Ca-dependent apoptosis induction, which may be exploited to enhance chemotherapy response in SMARCA4/2-deficient cancers.
Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
|
SMARCA4 mutation
|
cisplatin
8d
Patients with NSCLCBM who received ICI-90 had improved OS compared to no-ICI patients. Additionally, this benefit appears to be observed primarily in patients with KRAS mutations that may drive the overall benefit, which should be taken into account in the development of future trials.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
PD-L1 expression • KRAS mutation
8d
In conclusion, a high-precision AI system is proposed for the automated TPS assessment of PD-L1 expression in the 22c3 and SP263 assays in NSCLC. Our study also indicates the benefits of using an AI-assisted system to improve diagnostic repeatability and efficiency for pathologists.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
8d
Herein, the clinicopathological and genetic features of five unusual lung tumors will be reviewed, including thoracic SMARCA4-deficient undifferentiated tumor, NUT carcinoma, sclerosing pneumocytoma, primary pulmonary myxoid sarcoma/angiomatoid fibrous histiocytoma, and bronchiolar adenoma/ ciliated muconodular papillary tumor. Since recognition of these entities by pathologists is of increasing importance to guide prognosis and therapy, emphasis will be placed on practical tips to reach these rare diagnoses with confidence.
Review • Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
8d
We identified 365 genes potentially correlated with the radiotherapy response of NSCLC patients. The Risk Score model based on the identified 8 genes can predict the prognosis of NSCLC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • IGF1 (Insulin-like growth factor 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • ALPP (Alkaline Phosphatase, Placental) • CD4 (CD4 Molecule) • KCNJ12 (Potassium Inwardly Rectifying Channel Subfamily J Member 12)
8d
In mechanism, circ_0000677 acted as a sponge of microRNA-106b and further regulated CCDND1 gene expression in NSCLC cells by dual luciferase activity assay and their expression examination. Taken together, these findings suggest a role for circ_0000677/miR-106b/CCND1 regulation axis in promoting NSCLC growth and progression.
Journal
|
CCND1 (Cyclin D1) • MIR106B (MicroRNA 106b)
8d
The sensitivity of CTCs was improved from 75% to 83% by the combination with CA125 or NSE. CTCs may be helpful for the early detection of lung cancer in patients with a solitary pulmonary nodule.
Clinical • Journal • Circulating Tumor Cells
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
8d
We found that 10 of the 13 genes were differentially expressed in lung cancer, YTHDF1, RBM15, HNRNPC, KIAA1429, METTL3 and YTHDF2 are high expression while METTL14, ZC3H13, FTO and WTAP are low expression. HNRNPC and METTL3 genes were associated with the risk and prognosis of LUAD and could regard as biomarkers for early diagnosis and treatment, which provides a theoretical basis for LUAD.
Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • METTL3 (Methyltransferase Like 3) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
8d
Lipoproteins enriched in EVPs reflect the activated lipid metabolism in dormant cancer cells and may provide potential biomarkers or therapeutic targets for cisplatin-based therapy.
Journal
|
APOA1 (Apolipoprotein A-I) • APOE (Apolipoprotein E)
|
cisplatin
8d
Silence of UHRF1 expression in A549 cells resulted in the similar re-expression of p15, p16, p21 which is similar with miR-9 to 1 infection. Therefore, we concluded that UHRF1 is a new target for miR-9 to 1 to suppress cell proliferation by re-expression of tumor suppressors p15, p16, and p21 mediated by UHRF1.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
8d
Further studies revealed that ING5 overexpression inhibited IL-6/CXCL12 expression at both the mRNA and protein levels as well as morphological changes. We found for the first time that ING5 inhibits ESCC cell migration and invasion by downregulating the IL-6/CXCL12 signaling pathway.
Journal
|
IL6 (Interleukin 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
IL6 expression
8d
Thus, B-cell lymphoma-2 was identified as a direct target of microRNA-342-3p. These findings indicate that microRNA-342-3p inhibits the growth of nonsmall cell lung cancer by repressing the expression of B-cell lymphoma-2, which suggests that microRNA-342-3p could be a potential target for the treatment of nonsmall cell lung cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
8d
The mechanism of EGFR-TKI resistance of the third generation has become a focus of research in the field of targeted therapy. In this review, we summarize the research progress in resistance mechanisms of advanced NSCLC to osimertinib and the potential overcoming strategies and hope to provide a clinical basis and ideas for precision treatment of NSCLC.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
8d
There was no significant difference in the IC50 values between cells, with a <3.6-fold difference in responsiveness. In conclusion, these eight ALK variants had similar sensitivity to alectinib in vitro, indicating that it may not be possible to predict the response to alectinib just by determination of the ALK variant type in ALK fusion-positive NSCLCs.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • STAT3 (Signal Transducer And Activator Of Transcription 3) • KLC1 (Kinesin light chain 1)
|
ALK positive • ALK fusion • ALK V3a
|
Alecensa (alectinib)
8d
Thalidomide inhibits NSCLC angiogenesis and immune evasion via FGD5-AS1/miR-454-3p/ZEB1 axis-mediated regulation of VEGFA expression and PD-1/PD-L1 checkpoint.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • FGD5-AS1 (FGD5 Antisense RNA 1) • MIR454 (MicroRNA 454)
|
PD-L1 expression • PD-L1 overexpression • VEGFA expression • ZEB1 expression
|
thalidomide
8d
As regards to the in vivo studies, OSE loaded pegylated ERS based NPs demonstrated strong and moderate antiangiogenic activity for ERS-OSE 2 and ERS-OSE 3, respectively. With its cationic character, smaller particle size, relative superior EE%, homogenous amorphous polymeric matrix constitution indicated using solid state tests, prolonged release manner, highly selective to the human lung adenocarcinoma cell lines, could trigger apoptosis intrinsically and effectively, possess good in vivo antiangiogenic activity, ERS-OSE 2 formulation is chosen as a promising candidate and a potent drug delivery system to treat lung cancer.
Preclinical • Journal
|
CASP3 (Caspase 3)
|
oseltamivir
8d
In contrast, stably overexpressing MEG3 increased p21 levels and reduced Rb phosphorylation and Bcl-xL levels in Cd-exposed cells and reduced their cell cycle progression and apoptosis resistance. Together, these findings suggest that MEG3 down-regulation may play important roles in Cd-induced cell transformation and CSC-like property by promoting cell cycle progression and apoptosis resistance.
Journal
|
BCL2L1 (BCL2-like 1)
8d
Under the laser irradiation, APFHG can significantly increase the production of the intracellular reactive oxygen species and produce a synergistic therapeutic effect in inhibition of cellular growth and induction of cell cycle arrest and apoptosis on both Gef-sensitive and Gef-resistant EGFR-mutant NSCLC cells through PDT/molecular targeted therapy. This work indicates that fluorinated dendrimer could be a potent drug delivery platform to overcome hypoxia-related resistance and the co-delivery of EGFR-TKI and photosensitizer by the fluorinated dendrimer could be a promising therapeutic approach for reversal of EGFR-TKIs resistance in EGFR mutation-positive NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib